Photocure presenting at BioEquity Europe 2009 Conference

Please find enclosed the presentation that Christian Fekete, CFO of Photocure ASA, will have at the BioEquity Europe 2009 Conference in Munich, Germany today, Wednesday 10 June 2009.

Presentation (pdf)

For further information, contact:
President and CEO Kjetil Hestdal
E-mail: kh@photocure.no
Mobile: +47 913 19 535
Office: +47 22 06 22 10

CFO Christian Fekete
E-mail: cf@photocure.no
Mobile: +47 916 42 938
Office: +47 22 06 22 10
www.photocure.com

Photocure ASA is a Norwegian pharmaceutical company listed on the
Oslo Stock Exchange. The company develops and sells pharmaceuticals
and medical devices for the photodynamic treatment and diagnosis of
cancer.

Photocure has two proprietary pharmaceutical products on the market:
Metvix®, for the treatment of sun-damaged skin and certain types of
skin cancer, and Hexvix®, for the diagnosis of bladder cancer. In
addition, the company has developed a proprietary light source, the
Aktilite® lamp, which is used in combination with the Metvix cream.
Through worldwide studies, Photocure is continuously testing its
products for new indications, and the aim is to develop a pipeline of
follow-on products and technologies.

Photocure®, Metvix®, Hexvix® and Aktilite® are registered trademarks
of Photocure ASA.